PT  - JOURNAL ARTICLE
AU  - Zichen Wang
AU  - Amanda B. Zheutlin
AU  - Yu-Han Kao
AU  - Kristin L. Ayers
AU  - Susan J. Gross
AU  - Patricia Kovatch
AU  - Sharon Nirenberg
AU  - Alexander W. Charney
AU  - Girish N. Nadkarni
AU  - Paul F. O’Reilly
AU  - Allan C. Just
AU  - Carol R. Horowitz
AU  - Glenn Martin
AU  - Andrea D. Branch
AU  - Benjamin S. Glicksberg
AU  - Dennis S. Charney
AU  - David L. Reich
AU  - William K. Oh
AU  - Eric E. Schadt
AU  - Rong Chen
AU  - Li Li
TI  - Analysis of hospitalized COVID-19 patients in the Mount Sinai Health System using electronic medical records (EMR) reveals important prognostic factors for improved clinical outcomes
AID  - 10.1101/2020.04.28.20075788
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.28.20075788
4099  - http://medrxiv.org/content/early/2020/05/04/2020.04.28.20075788.short
4100  - http://medrxiv.org/content/early/2020/05/04/2020.04.28.20075788.full
AB  - Importance There is an urgent need to understand patient characteristics of having COVID-19 disease and evaluate markers of critical illness and mortality.Objective To assess association of clinical features on patient outcomes.Design, Setting, and Participants In this observational case series, patient-level data were extracted from electronic medical records for 28,336 patients tested for SARS-CoV-2 at the Mount Sinai Health System from 2/24/ to 4/15/2020, including 6,158 laboratory-confirmed cases.Exposures Confirmed COVID-19 diagnosis by RT-PCR assay from nasal swabs.Main Outcomes and Measures Effects of race on positive test rates and mortality were assessed. Among positive cases admitted to the hospital (N = 3,273), effects of patient demographics, hospital site and unit, social behavior, vital signs, lab results, and disease comorbidities on discharge and death were estimated.Results Hispanics (29%) and African Americans (25%) had disproportionately high positive case rates relative to population base rates (p<2e-16); however, no differences in mortality rates were observed in the hospital. Outcome differed significantly between hospitals (Gray’s T=248.9; p<2e-16), reflecting differences in average baseline age and underlying comorbidities. Significant risk factors for mortality included age (HR=1.05 [95% CI, 1.04-1.06]; p=1.15e-32), oxygen saturation (HR=0.985 [95% CI, 0.982-0.988]; p=1.57e-17), care in ICU areas (HR=1.58 [95% CI, 1.29-1.92]; p=7.81e-6), and elevated creatinine (HR=1.75 [95% CI, 1.47-2.10]; p=7.48e-10), alanine aminotransferase (ALT) (HR=1.002, [95% CI 1.001-1.003]; p=8.86e-5) white blood cell (WBC) (HR=1.02, [95% CI 1.01-1.04]; p=8.4e-3) and body-mass index (BMI) (HR=1.02, [95% CI 1.00-1.03]; p=1.09e-2). Asthma (HR=0.78 [95% CI, 0.62-0.98]; p=0.031) was significantly associated with increased length of hospital stay, but not mortality. Deceased patients were more likely to have elevated markers of inflammation. Baseline age, BMI, oxygen saturation, respiratory rate, WBC count, creatinine, and ALT were significant prognostic indicators of mortality.Conclusions and Relevance While race was associated with higher risk of infection, we did not find a racial disparity in inpatient mortality suggesting that outcomes in a single tertiary care health system are comparable across races. We identified clinical features associated with reduced mortality and discharge. These findings could help to identify which COVID-19 patients are at greatest risk and evaluate the impact on survival.Competing Interest StatementDr. William Oh is a paid consultant to Astellas, Astra Zeneca, Bayer, Janssen, Sanofi, Sema4, and TeneoBio. No other disclosures were reported. Funding StatementThe authors affiliated with Sema4 declare no external funding was received for this study.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual level data are not available for this study. For aggregate data please contact the corresponding authors.